Phase 2 Deucravacitinib, oral, selective TYK2i results: Analyses confirmed the efficacy of deucravacitinib vs PBO across TNFi & body weight subgroups. Safety profile similar to that found in PsO trials. Abstract #OP0227 #EULAR2021 @RheumNow https://t.co/BBvn5MaXPp https://t.co/jWFhpmkuC5